ERBB2 and cancer: Similarly, specific localization of PS agents at the cancer site was achieved by incorporating anti-HER2 antibodies on hybrid nanodrug system (Au@PEG-ZnPc/anti-HER2) to target specific binding to the HER2 receptors on the cell surface [46].